Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News NuCana PLC NCNA

NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-3373, and NUC-7738. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). 5-FU is a prescribed anti-cancer agent. NUC... see more

Recent & Breaking News (NDAQ:NCNA)

NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire November 25, 2024

NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel

GlobeNewswire November 11, 2024

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States

GlobeNewswire September 25, 2024

NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024

GlobeNewswire September 14, 2024

NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study

GlobeNewswire August 29, 2024

NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire August 15, 2024

NuCana to Present at the Jefferies Global Healthcare Conference

GlobeNewswire May 30, 2024

NuCana to Present at TD Cowen's 5th Annual Oncology Innovation Summit

GlobeNewswire May 21, 2024

NuCana Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire May 16, 2024

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

GlobeNewswire May 1, 2024

NuCana Announces Completion of ADS Ratio Change

GlobeNewswire April 16, 2024

NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study

GlobeNewswire April 9, 2024

NuCana Announces Plan to Implement ADS Ratio Change

GlobeNewswire March 27, 2024

NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update

GlobeNewswire March 20, 2024

NuCana to Present at TD Cowen's 44th Annual Health Care Conference

GlobeNewswire February 27, 2024

NuCana to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

GlobeNewswire February 6, 2024

NuCana Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire November 16, 2023

NuCana Announces Listing Transfer to Nasdaq Capital Market

GlobeNewswire November 10, 2023

NuCana to Present at the Jefferies London Healthcare Conference

GlobeNewswire November 8, 2023

NuCana to Participate in the Truist Securities 2023 BioPharma Symposium

GlobeNewswire November 1, 2023